PHIO — Phio Pharmaceuticals Corp.

Nasdaq · Health Care · Pharmaceuticals · CIK 1533040 ·
Last close
$1.08
Market Cap
$12.55M
52W High
$1.35
52W Low
$0.98
ADV30
139,691
Next earnings
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -4,167,000 -4,003,000 17,412,000 17,031,000 950,000
Dec 2025 0 -2,534,000 -2,371,000 21,487,000 21,031,000 1,340,000
Sep 2025 0 -2,505,000 -2,392,000 11,505,000 10,705,000 1,666,000
Jun 2025 0 -2,309,000 -2,166,000 11,301,000 10,775,000 1,206,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,979,000
Investing CF
$-12,000
Financing CF
$23,640,000
CapEx
$-12,000
Dividends Paid
Buybacks
$-1,000
EPS Diluted TTM
$-2.84
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-155,054,000
Inventory
Receivables
ST Investments
EBIT TTM
$-9,220,000
Pretax Income TTM
$-8,698,000
Interest Exp TTM
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -9,220,000 -8,698,000 21,487,000 1,340,000 -7,979,000
Dec 2024 0 -7,387,000 -7,150,000 5,738,000 1,015,000 -7,112,000
Dec 2023 0 -10,698,000 -10,826,000 9,364,000 1,634,000 -10,749,000
Dec 2022 0 -11,462,000 -11,480,000 12,814,000 1,976,000 -12,129,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.86

Peers — same industry

TickerNameMarket CapLastDaily %
BIOE Bio Essence Corp $12.83M $0.27
GOVX GeoVax Labs, Inc. $12.12M $3.49
MBRX Moleculin Biotech, Inc. $13.07M $2.45
CALC CalciMedica, Inc. $12.01M $0.76
BFRG BullFrog AI Holdings, Inc. $13.13M $0.71

News headlines (Yahoo Finance, 1h cache)

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
2026-05-26 11:00 · Yahoo
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
2026-05-12 11:00 · Yahoo
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
2026-05-07 20:05 · Yahoo
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
2026-04-13 11:00 · Yahoo
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
2026-04-09 11:00 · Yahoo
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
2026-03-30 11:00 · Yahoo
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancemen
2026-03-23 11:00 · Yahoo
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
2026-03-16 15:30 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
2026-03-13 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
2026-03-10 14:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.